24 May 2013
Keywords: gsk/xenoport, drug, fails, ph, ii, dpn, study
Article | 28 April 2009
UK drug major GlaxoSmithKline and USA-based XenoPort reported data showing that gabapentin enacarbil missed its primary endpoint in a
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 April 2009
27 April 2009
23 May 2013
© 2013 thepharmaletter.com